Latest Breaking News On - Genomic atlas - Page 1 : comparemela.com

Veracyte, Inc. (Nasdaq: VCYT) announced today new data demonstrating the ability of the Percepta ® Genomic Atlas to detect alterations that may inform lung cancer treatment decisions for patients from the same small biopsy that was used for diagnosis. Study findings presented today at the American Thoracic Society (ATS) 2021 International Conference show that the test accurately detects known lung-cancer gene variants using small biopsy samples, which may help guide treatment with targeted therapies. The in-development Percepta Genomic Atlas will provide comprehensive genomic profiling information on cancerous lung nodules, masses or lymph nodes, utilizing small samples from the same biopsy procedure used for diagnosis (i.e., transbronchial needle aspirate biopsies or TBNA). The test uses targeted DNA and whole-transcriptome RNA sequencing to detect alterations in more than 50 genes known to be present in lung cancer. Veracyte plans to launch the test in the second half of 2021 as

United statesSouth san franciscoGiuliac kennedyNanostring technologies incVeracyte incInternational conferenceAmerican thoracic societyNational comprehensive cancer networkGenomic atlasPercepta genomic atlasPercepta genomicAnnual reportNanostring technologiesஒன்றுபட்டது மாநிலங்களில்தெற்கு சான் பிரான்சிஸ்கோசர்வதேச மாநாடு